Quantcast

Industry news that matters to you.  Learn more

Profil Institute Unites Leading Experts in Biomarker Discovery and Clinical Research to Address the Medical Challenges of NAFLD/NASH

Profil Institute for Clinical Research, a clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today a collaboration of experts in biomarker discovery and clinical research in the fields of metabolism, diabetes and obesity to address the medical challenges of NAFLD and NASH.

KineMed Receives Grant to Apply Novel Method for Measuring Muscle Mass in Infants and Children for the Diagnosis and Prevention of Malnutrition and Growth Stunting

KineMed, Inc. (www.kinemed.com) recently announced that it has been awarded a three-year grant by the Bill & Melinda Gates Foundation to apply its novel, proprietary non-invasive measurement of skeletal muscle mass to pre-term and full-term infants and young children. The Principal Investigator, William Evans, Ph.D., is head of the KineMed Division of Muscle and Health. The study will, for the first time, measure changes in skeletal muscle mass during one year of growth. The information from this project will provide new information to better assess the effects of nutritional status and other factors that result in the loss of muscle.

KineMed Biomarker Studies in Chronic Lymphocytic Leukemia Reveal Groundbreaking Approach for Guiding Patient Management and Drug Development

KineMed, Inc. recently announced that two Chronic Lymphocytic Leukemia (CLL) studies utilizing KineMed’s proprietary kinetic biomarker technology, will be presented at the American Society of Hematology Annual Meeting taking place this weekend in San Francisco, California. KineMed’s CLL research collaborators, Jan A. Burger, MD, Ph.D., of the MD Anderson Cancer Center, and Elizabeth J. Murphy, MD, DPhil, from the at the University of California San Francisco Department of Medicine and representing the CLL Research Consortium investigators, will present the studies at the conference.

KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson’s Disease, and Diabetic Neuropathy

KineMed, Inc. recently announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: “Compositions and Methods of Treatment Using Modulators of Motoneuron Disease.” The patent allowance covers the treatment of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, Parkinson’s disease, and diabetic neuropathy using the microtubule target modulating agent, noscapine, alone or in combination with a variety of other agents.

KineMed and CHDI Foundation Extend Huntington’s Disease Collaboration

KineMed, Inc. and CHDI Foundation, Inc. recently announced an extension of their collaboration that uses KineMed’s translational biomarker platform to characterize and track the pathogenesis of Huntington’s disease (HD) and evaluate potentially therapeutic interventions.